Find promising cancer trials in minutes

Enter a patient's cancer details below, such as molecular profile and prior treatments, and HealthScout will rapidly:

  1. Identify trials precisely matching their information
  2. Sort trials by relevance, and show a custom summary and analysis for each trial

HealthScout is non-commercial and free to use. It works for advanced/metastatic solid tumors (breast cancer, lung cancer, and 20 other cancer types).

New blog post: Head-to-head trial match results

Start a patient

How it works

1/Our AI translates the patient's info into a computer-readable format

"...had progression on carbo/taxol/Keytruda..."

  • Had treatment regimen of:
    • Carboplatin (drug class: cytotoxic chemotherapy)
    • Paclitaxel (drug class: cytotoxic chemotherapy)
    • Pembrolizumab (drug class: PD-1/PD-L1 inhibitor)
  • Result of regimen: progression

2/This data is used to get a list of matching trials

Trial inclusion criterion:
Progression on regimen containing chemotherapy and PD-1/PD-L1 inhibitor

  • Regimen must contain:
    • ≥1 drug in class: cytotoxic chemotherapy
    • ≥1 drug in class: PD-1/PD-L1 inhibitor
  • Result of regimen must have been: progression
✓ Successful match!

3/Learn about the matching trials and find the ones that are the best fit

Tags in the trials list help you zero in on the best trials. Trials with better tags show up first.

Molecular match Active drug High burden on patient

In the AI Picks tab, chat with an AI agent that learns about matching trials and highlights promising ones.

Assistant

Great — since you’re flexible, I pulled a broad set and focused first on trials most tailored to EGFR exon 20 insertion NSCLC after platinum chemotherapy. Below are the ones that look most promising for [Name]. I called out when a study has a close site (≤100 miles from the patient).

Our analysis helps identify the most promising drugs and trials:

Zongertinib clinical results

Zongertinib has shown promising preliminary results in ongoing clinical trials. In the Beamion LUNG-1 trial (NCT04886804), a Phase Ia/Ib first-in-human study, zongertinib demonstrated high response rates, particularly among NSCLC patients.

The drug was well tolerated, with low rates of EGFR-mediated adverse events and no discontinuations due to adverse events recorded during the Phase Ib trial. Initial efficacy data from Phase Ib reflected a high objective response rate (ORR) of 74% and a disease control rate (DCR) of 91% [1].

[1] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor, in patients with HER2-positive advanced NSCLC.

About HealthScout

Who is HealthScout for?

We hope it will be useful for oncologists, patients, patient navigators, research coordinators, and anyone who is interested in helping patients to find promising clinical trials for them. Because the decision to consider a clinical trial is complex, patients should always discuss with their oncologist to help guide them and not just rely on HealthScout.

Who created HealthScout?

The HealthScout team is led by Michael Gensheimer MD, a radiation oncologist at Stanford University. Dr. Gensheimer noticed that many of his patients were interested in clinical trials but were struggling to find ones that were a good fit. This inspired him to create HealthScout. He has been a faculty member at Stanford since 2015 and his deep involvement in clinical trials includes serving as an investigator for phase 1 studies, leading investigator-initiated phase 2 trials, and enrolling patients on large phase 3 trials.

Is the site secure?

Yes, user data is encrypted at all times and HealthScout lives on the secure Render.com platform. Also, you never need to enter any personal information like date of birth. We do ask for a name for each patient, but you can just use their initials or first name.

Is HealthScout free to use?

Yes it is. HealthScout is non-commercial and we do not sell user data to any third parties.